Alyeska Investment Group
ELDN icon

Alyeska Investment Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Alyeska Investment Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-933,475
Closed -$2.53M – 626
2025
Q2 		$2.53M Hold
933,475
– – 0.01% 477
2025
Q1 		$3.16M Hold
933,475
– – 0.01% 393
2024
Q4 		$3.85M Buy
933,475
+433,475
+87% +$1.71M 0.01% 415
2024
Q3 		$1.25M Hold
500,000
– – 0.01% 450
2024
Q2 		$1.32M Buy
+500,000
New +$1.19M 0.01% 444
2016
Q3 		– Sell
-1,989
Closed -$1.78M – 479
2016
Q2 		$1.78M Buy
1,989
+40
+2% +$44.1K 0.02% 367
2016
Q1 		$1.77M Buy
1,949
+395
+25% +$388K 0.02% 339
2015
Q4 		$2.2M Sell
1,554
-529
-25% -$922K 0.02% 299
2015
Q3 		$3.49M Buy
2,083
+191
+10% +$393K 0.04% 290
2015
Q2 		$4.08M Buy
1,892
+138
+8% +$267K 0.05% 290
2015
Q1 		$3.21M Buy
1,754
+129
+8% +$285K 0.04% 323
2014
Q4 		$3.88M Sell
1,625
-60
-4% -$142K 0.07% 290
2014
Q3 		$4.13M Buy
+1,685
New +$4.79M 0.09% 239

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Alyeska Investment Group's ELDN Position: Q3 2025 in Review

Alyeska Investment Group sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 933,475 shares — an estimated $2.53M sold.

Alyeska Investment Group first reported a position in ELDN in Q3 2014 and held it in 13 quarters. The position peaked at $4.13M in Q3 2014. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Alyeska Investment Group reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 933,475 Eledon Pharmaceuticals shares in Q3 2025, an estimated $2.53M.
  • Alyeska Investment Group first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 13 quarters.
  • Alyeska Investment Group's Eledon Pharmaceuticals position peaked at $4.13M in Q3 2014.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.